Crohn's disease trials recruiting in Ohio

All Crohn's disease trials nationally

Cities in Ohio

Recruiting trials in Ohio

• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT06405087 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Cleveland
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
  NCT06663332 · Phase: Phase 3 · Ages: 3 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184944 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Ohio: Columbus, Westlake
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Cincinnati, Liberty Township
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
  NCT07499232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Mentor
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05923073 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Dayton
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
  NCT07577843 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Mentor
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
  NCT05509777 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Dayton
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
  NCT06045754 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: Cincinnati, Columbus, Mentor, Westlake
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Cincinnati, Dayton, Liberty Township, Mentor
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Ohio: Cleveland
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Cleveland
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
  NCT06100289 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Cleveland
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Mentor
• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05995353 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Cleveland
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819891 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Ohio: Beavercreek, Cleveland
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Ohio: Beavercreek, Brunswick, Cincinnati, Cleveland
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Ohio: Mentor
• ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
  NCT06810518 · Phase: Not specified · Ages: 22 Years and older · Sex: All (male and female) · Ohio: Westlake
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Ohio: Canton, Columbus, Dayton, Springboro
• Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
  NCT05781152 · Phase: Phase 4 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
  NCT06332534 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Cleveland
• Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
  NCT06670638 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
  NCT06456593 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Hilliard
• Evaluation of the SMART IBD App in Pediatric IBD
  NCT07195123 · Phase: Not applicable (e.g. observational or device study) · Ages: 13 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: Westlake
• Non-nutritive Sweeteners in Inflammatory Bowel Disease
  NCT07769437 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: Chagrin Falls, Cleveland, Westlake
• Precise Infliximab Exposure and Pharmacodynamic Control
  NCT05660746 · Phase: Phase 2, Phase 3 · Ages: 6 Years to 22 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
  NCT07697456 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Englewood, Westlake
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Cincinnati, Columbus
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Treatment of Moderate to Severe Refractory Crohn's Disease
  NCT06721962 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cleveland
• Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
  NCT07680283 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Zymfentra (Infliximab-dyyb) REal World Cohort STudy
  NCT07237516 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati